The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.

Recruiting now · Not applicable

Conditions studied: HER2-positive Breast Cancer

In brief

This study is the spatial transcriptomic approach for revealing the resistance mechanism of trastuzumab deruxtexan in HER2 positive breast cancer patients.

Key facts

Study ID

NCT06330012

Run by

Samsung Medical Center

People needed

50

Starts

2024-03-18

Expected to finish

2027-12-31

Last updated by the study team

2024-03-26

Who can join

Age: any. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• HER2 positive breast cancer
• Stage IV disease
• Treated with T-Dxd
• Available FFPE samples

You may not qualify if…

• TNBC breast cancer
• Hormone receptor positive breast cancer
• Non-available FFPE samples
• Treated except T-Dxd

Where it is running

• Ji-Yeon Kim — Seoul, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.